Thomas D. Penning

FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

Macrocyclic MCL-1 Inhibitors and Methods of Use

Macrocyclic MCL-1 Inhibitors and Methods of Use

Macrocyclic MCL-1 Inhibitors and Methods of Use

Macrocyclic MCL-1 inhibitors and methods of use

Macrocyclic MCL-1 inhibitors and methods of use

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Pyrrolopyridine inhibitors of kinases

5-substituted indazoles as kinase inhibitors

1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS

Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases

CDK9 kinase inhibitors

Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors

Pyridine CDK9 kinase inhibitors

Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors

PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS

Inhibitors of poly(ADP-ribose)polymerase

Pyridopyrimidinone inhibitors of kinases

Pyridopyrimidinone inhibitors of kinases

Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases

Chemical entities to be used for Wee1 inhibition for the treatment of cancer

PARP INHIBITORS FOR THE TREATMENT OF CIPN

Tricyclic inhibitors of kinases

Picolinamide inhibitors of kinases

BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS

COMBINATION THERAPY WITH PARP INHIBITORS

BENZOXAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE

Pyrrolopyrazinone inhibitors of kinases

Phthalazin-(2H)-one inhibitors of kinases

Pyrrolopyridine inhibitors of kinases

COMBINATION THERAPY WITH PARP INHIBITORS

COMBINATION THERAPY WITH PARP INHIBITORS

Pyrrolopyridine inhibitors of kinases

Pyrrolopyrazine inhibitors of kinases

2-substituted-1H-benzimidazole-4-carboxamides are PARP inhibitors

Benzthiazole inhibitors of poly(ADP-ribose)polymerase

Potent PARP inhibitors

5-substituted indazoles as kinase inhibitors

Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors

PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS

Benzimidazole poly(ADP ribose)polymerase inhibitors

COMBINATION THERAPY WITH PARP INHIBITORS

Inhibitors of poly(ADP-ribose)polymerase

PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS

Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeutics

Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase

INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE

COMBINATION THERAPY WITH PARP INHIBITORS

Poly(ADP-ribose)polymerase inhibitors

Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases

Potent PARP Inhibitors

Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors

Combination Therapy with Parp Inhibitors

SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS

Pyrazoloquinolones are potent PARP inhibitors

1H-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent PARP inhibitors

Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors

2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors

1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Heteroarylakanoic acids as intergrin receptor antagonists

3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

Heteroarylalkanoic acids as integrin receptor antagonists

Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation

Lactone integrin antagonists

Heteroarylalkanoic acids as integrin receptor antagonists derivatives

Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors

Pyrazole compounds as integrin receptor antagonists derivatives

Thiazole compounds as integrin receptor antagonists derivatives